Zydus Cadila gets USFDA’s final nod for Deferasirox tablets for oral suspension

08 May 2020 Evaluate

Zydus Cadila has received final approval from the US Food and Drug Administration (USFDA) to market Deferasirox Tablets for Oral Suspension in the strengths of 125 mg, 250 mg and 500 mg.  The drug will be manufactured at the group’s manufacturing facility at SEZ, Ahmedabad.  

Deferasirox binds to iron and removes it from the bloodstream. It is used to treat iron overload caused by blood transfusions in adults and children who are at least 2 years old. It is also used to treat chronic iron overload syndrome caused by a genetic blood disorder (non-transfusion dependent thalassemia) in adults and children who are at least 10 years old.

The group now has 289 approvals and has so far filed over 386 ANDAs since the commencement of the filing process in FY 2003-04.

Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×